---
title: "CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283573645.md"
description: "CStone Pharmaceuticals (HK:2616) announced it will present updated clinical data for its trispecific antibody CS2009 at the ASCO 2026 Annual Meeting. The data highlights progress from a global Phase I/II program in non-small cell lung cancer and advanced solid tumors, showing strong safety and encouraging efficacy. The company is preparing to launch Phase III multi-regional trials to enhance its position in immuno-oncology and expand its global registration strategy. CStone focuses on innovative oncology therapies and has a market cap of HK$14.39B."
datetime: "2026-04-22T00:09:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283573645.md)
  - [en](https://longbridge.com/en/news/283573645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283573645.md)
---

# CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

CStone Pharmaceuticals ( (HK:2616) ) has issued an update.

CStone Pharmaceuticals said it will present updated clinical data for its internally developed trispecific antibody CS2009 at the ASCO 2026 Annual Meeting, highlighting progress from a global Phase I/II program in non-small cell lung cancer and advanced solid tumors. The company reported strong safety, encouraging efficacy in first-line and later-line NSCLC, signals of activity in colorectal and other “cold” tumors, and is preparing to launch Phase III multi-regional trials, potentially strengthening its position in immuno-oncology and expanding its global registration strategy.

**More about CStone Pharmaceuticals**

CStone Pharmaceuticals is a China-focused biopharmaceutical company specializing in the discovery and development of innovative oncology therapies. Its pipeline includes immuno-oncology assets and targeted drugs aimed at treating solid tumors, with a growing emphasis on advanced biologics such as multispecific antibodies for global markets.

**Average Trading Volume:** 14,368,076

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$14.39B

For a thorough assessment of 2616 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)

## Related News & Research

- [CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone](https://longbridge.com/en/news/286244356.md)
- [CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007](https://longbridge.com/en/news/283271354.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [00:18 ETDatar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren](https://longbridge.com/en/news/286712658.md)
- [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)